Has Mukka Proteins declared dividend?

No Dividend History Available

Who are the peers of the Mukka Proteins?

Mukka Proteins' peers include Godavari Bioref., HMA Agro Inds., Aayush Wellness, and others, with Aayush Wellness showing excellent management risk and the highest 1-year return at 1374.42%, while Mukka Proteins has a 1-year return of -45.04%. Growth is good for Mukka Proteins and a few others, but its capital structure is below average compared to peers.

Peers: The peers of Mukka Proteins are Godavari Bioref., HMA Agro Inds., Andrew Yule & Co, Aayush Wellness, Jindal Photo, Vadilal Enterp., SKM Egg Prod., Foods & Inns, and Apex Frozen Food.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aayush Wellness and the rest have Average management risk. Growth is Good at Mukka Proteins, Vadilal Enterp., SKM Egg Prod., and Aayush Wellness, while the rest show Below Average or Average growth. Capital Structure is Good at Aayush Wellness, Vadilal Enterp., and SKM Egg Prod., while Below Average capital structure is found at Mukka Proteins, Andrew Yule & Co, HMA Agro Inds., Jindal Photo, Foods & Inns, and the rest.<BR><BR>Return Snapshot: Aayush Wellness has the highest 1-year return at 1374.42%, while HMA Agro Inds. has the lowest at -42.55%, with Mukka Proteins' 1-year return of -45.04% being lower than both. Additionally, Jindal Photo and Foods & Inns are among the peers with negative six-month returns.

What does Mukka Proteins do?

Mukka Proteins Ltd is a micro-cap FMCG company that specializes in protein products, with recent net sales of ₹3,816 Cr and a net profit of ₹136 Cr as of March 2025. The company has a market cap of ₹897 Cr and key financial metrics include a P/E ratio of 19.00 and a debt-equity ratio of 0.93.

Overview:<BR>Mukka Proteins Ltd operates in the FMCG industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Mukka Proteins Limited was originally incorporated as "Mukka Sea Food Industries" in Karnataka on March 13, 2003. It was converted from a partnership firm to a private company on November 04, 2010. The latest quarterly results report net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,816 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 136 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 897 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.93 <BR>Return on Equity: 10.47% <BR>Price to Book: 2.03 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Mukka Proteins?

The top shareholders of Mukka Proteins include Mohammed Haris K, who holds 30.23%, followed by 7 Foreign Institutional Investors with 2.63%, and Neomile Growth Fund - Series I with 1.98%. Individual investors own 19.85%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Mukka Proteins include the promoters, who hold the majority of the shares. The promoter with the highest holding is Mohammed Haris K, who owns 30.23% of the company. Additionally, there are 7 Foreign Institutional Investors (FIIs) holding a combined 2.63% of the shares. The highest public shareholder is Neomile Growth Fund - Series I, which holds 1.98%. Individual investors collectively own 19.85% of the company. There are no pledged promoter holdings, and no mutual funds are currently invested in Mukka Proteins.

How big is Mukka Proteins?

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, with recent net sales of 1006.42 Cr and a net profit of 46.16 Cr. The company reported shareholder's funds of 396.09 Cr and total assets of 940.79 Cr for the annual period ending March 2024.

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Mukka Proteins reported Net Sales of 1006.42 Cr and a Net Profit of 46.16 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds of 396.09 Cr and Total Assets amounting to 940.79 Cr.

Are Mukka Proteins latest results good or bad?

Mukka Proteins' latest financial results are disappointing, with net sales down 32.1% and a significant decline in profit metrics, indicating a challenging period for the company. The overall performance suggests unfavorable conditions for its business model.

Mukka Proteins has reported disappointing financial results for the quarter ending June 2025. The company experienced a significant decline in key metrics, with net sales dropping to Rs 170.77 crore, which is a 32.1% decrease compared to the average sales of Rs 251.61 crore over the previous four quarters. <BR><BR>Profit Before Tax (PBT) fell drastically to Rs -0.20 crore, marking a decline of 101.8% from the average PBT of Rs 10.93 crore in prior quarters. Profit After Tax (PAT) also saw a sharp drop to Rs 1.52 crore, down 86.8% from an average of Rs 11.54 crore. <BR><BR>Additionally, the company faced rising interest costs, with expenses increasing by 37.44% over the preceding nine months, indicating higher borrowings. Notably, non-operating income comprised 108.47% of PBT, raising concerns about the sustainability of its business model. The Earnings per Share (EPS) fell to Rs 0.05, reflecting a decline in profitability for shareholders.<BR><BR>Overall, these results indicate a challenging period for Mukka Proteins, suggesting that the latest financial performance is indeed unfavorable.

When is the next results date for Mukka Proteins?

Mukka Proteins will announce its results on 12 November 2025.

Mukka Proteins will declare its results on 12 November 2025.

How has been the historical performance of Mukka Proteins?

Mukka Proteins has shown fluctuating performance, with net sales declining to 1,006.42 Cr in March 2025 from 1,379.83 Cr in March 2024, alongside decreases in profitability, while total assets increased to 1,076.32 Cr. The company faced a challenging year marked by negative cash flow and reduced profits.

Answer:<BR>The historical performance of Mukka Proteins shows a fluctuating trend in net sales and profitability over the years, with a notable decline in the most recent fiscal year.<BR><BR>Breakdown:<BR>Mukka Proteins reported net sales of 1,006.42 Cr for the year ending March 2025, a decrease from 1,379.83 Cr in March 2024 and 1,177.12 Cr in March 2023, but an increase from 770.50 Cr in March 2022. Total operating income mirrored this trend, reaching 1,006.42 Cr in March 2025. The company's total expenditure, excluding depreciation, was 911.53 Cr in March 2025, down from 1,274.36 Cr in March 2024, while operating profit (PBDIT) was 110.01 Cr, showing a decline from 121.79 Cr in the previous year. Profit before tax also decreased to 59.20 Cr in March 2025 from 84.35 Cr in March 2024. Consequently, profit after tax fell to 47.03 Cr from 71.20 Cr. The company's total assets increased to 1,076.32 Cr in March 2025, up from 940.79 Cr in March 2024, and total liabilities also rose to 1,076.32 Cr from 940.79 Cr. Cash flow from operating activities remained negative at -111.00 Cr in March 2025, although cash and cash equivalents decreased to 3.00 Cr from 94.00 Cr in March 2024. Overall, Mukka Proteins experienced a challenging year with declining sales and profits, despite an increase in total assets and liabilities.

Should I buy, sell or hold Mukka Proteins?

Is Mukka Proteins overvalued or undervalued?

As of November 14, 2025, Mukka Proteins is considered very attractive and undervalued with a PE ratio of 16.74 and an EV to EBITDA of 12.74, outperforming peers like Avanti Feeds and Apex Frozen Foods, and has delivered an 8.16% return compared to the Sensex's 1.62%.

As of 14 November 2025, Mukka Proteins has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, supported by a PE ratio of 16.74, an EV to EBITDA ratio of 12.74, and a PEG ratio of 0.00, indicating strong potential for growth relative to its price. <BR><BR>In comparison with peers, Avanti Feeds has a PE ratio of 16.54 and an EV to EBITDA of 10.04, while Apex Frozen Foods shows a significantly higher PE ratio of 43.53, suggesting that Mukka Proteins is positioned favorably within its industry. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, with an 8.16% return compared to the Sensex's 1.62%, reinforcing the notion of its undervaluation.

Is Mukka Proteins technically bullish or bearish?

As of December 3, 2025, Mukka Proteins is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and RSI across different timeframes.

As of 3 December 2025, the technical trend for Mukka Proteins has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are also bearish. Although the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the bearish signals from the moving averages and Bollinger Bands. The RSI shows no signal on the weekly timeframe, while it is bullish on the monthly, indicating mixed signals across different timeframes. Overall, the bearish trend is currently stronger, reflecting the recent price decline from the previous close.

Why is Mukka Proteins falling/rising?

As of 20-Dec, Mukka Proteins Ltd's stock is experiencing a short-term rise of 0.42% after two days of decline, but it has fallen significantly by 41.41% year-to-date and is trading near its 52-week low. The overall bearish trend, low investor participation, and poor financial performance indicate that this recent increase may not be sustainable.

As of 20-Dec, Mukka Proteins Ltd's stock price is currently rising, with a change of 0.1 (0.42%) to a current price of 24.05. This increase comes after two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 0.6% today, which may contribute to the positive movement in its price.<BR><BR>However, it is important to note that despite this short-term rise, the stock has been experiencing a significant decline over the longer term. Year-to-date, it has fallen by 41.41%, and over the past year, it has decreased by 39.66%. The stock is also trading close to its 52-week low, just 1.04% away from Rs 23.8. Furthermore, Mukka Proteins is trading below its moving averages across various time frames, indicating a generally bearish trend.<BR><BR>Investor participation has also been declining, with a 7.26% drop in delivery volume compared to the 5-day average, suggesting reduced interest from investors. This decline in participation, coupled with the company's poor financial performance—such as a low Return on Capital Employed (ROCE) of 9.16% and negative results for the last seven consecutive quarters—highlights ongoing challenges that could overshadow the recent price increase.<BR><BR>In summary, while Mukka Proteins' stock is currently rising due to a short-term trend reversal and sector outperformance, the broader context of significant long-term declines, low investor participation, and poor financial metrics suggests that this rise may not be sustainable.

Which are the latest news on Mukka Proteins?